CN109789100A - 包含微粉化托卡朋的持续释放组合物 - Google Patents

包含微粉化托卡朋的持续释放组合物 Download PDF

Info

Publication number
CN109789100A
CN109789100A CN201780060604.7A CN201780060604A CN109789100A CN 109789100 A CN109789100 A CN 109789100A CN 201780060604 A CN201780060604 A CN 201780060604A CN 109789100 A CN109789100 A CN 109789100A
Authority
CN
China
Prior art keywords
tolcapone
tablet
tablet according
cellulose
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780060604.7A
Other languages
English (en)
Chinese (zh)
Inventor
A.纳迪里卡特
J.M.苏涅内格雷
N.雷格博拉诺
R.因萨博罗纳
O.赫尔塔斯冈宾
S.埃斯特巴格拉斯
G.佩里科摩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of CN109789100A publication Critical patent/CN109789100A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780060604.7A 2016-07-29 2017-07-28 包含微粉化托卡朋的持续释放组合物 Pending CN109789100A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7 2016-07-29
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (1)

Publication Number Publication Date
CN109789100A true CN109789100A (zh) 2019-05-21

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780060604.7A Pending CN109789100A (zh) 2016-07-29 2017-07-28 包含微粉化托卡朋的持续释放组合物

Country Status (12)

Country Link
US (2) US11883538B2 (enExample)
EP (2) EP3275433A1 (enExample)
JP (1) JP7047236B2 (enExample)
KR (1) KR102484678B1 (enExample)
CN (1) CN109789100A (enExample)
AU (1) AU2017303333B2 (enExample)
DK (1) DK3490535T3 (enExample)
ES (1) ES2891355T3 (enExample)
MX (1) MX391116B (enExample)
PT (1) PT3490535T (enExample)
RU (1) RU2750670C2 (enExample)
WO (1) WO2018019997A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1319005A (zh) * 1998-09-14 2001-10-24 欧里恩公司 含有恩他卡朋和硝替卡朋以及交联纤维素衍生物的药物组合物
US20070003619A1 (en) * 2002-12-20 2007-01-04 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
CN101184483A (zh) * 2005-06-08 2008-05-21 奥赖恩公司 含恩他卡朋的口服剂型
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
CN103889407A (zh) * 2011-10-24 2014-06-25 索姆创新生物技术公司 用于甲状腺素运载蛋白相关的淀粉样变性的新疗法
WO2015069773A1 (en) * 2013-11-05 2015-05-14 Synagile Corporation Devices and methods for continuous drug delivery via the mouth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DE69733752T2 (de) 1996-05-20 2006-06-01 G.D. Searle Llc, Chicago Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
SI2640358T1 (en) * 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
MX355309B (es) 2011-03-14 2018-04-16 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno.
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CN105209029A (zh) * 2013-03-13 2015-12-30 纽罗德姆有限公司 帕金森病的治疗方法
CA3175785A1 (en) * 2014-09-04 2016-03-10 Intrance International Ab Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1319005A (zh) * 1998-09-14 2001-10-24 欧里恩公司 含有恩他卡朋和硝替卡朋以及交联纤维素衍生物的药物组合物
US20070003619A1 (en) * 2002-12-20 2007-01-04 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
CN101184483A (zh) * 2005-06-08 2008-05-21 奥赖恩公司 含恩他卡朋的口服剂型
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
CN103889407A (zh) * 2011-10-24 2014-06-25 索姆创新生物技术公司 用于甲状腺素运载蛋白相关的淀粉样变性的新疗法
WO2015069773A1 (en) * 2013-11-05 2015-05-14 Synagile Corporation Devices and methods for continuous drug delivery via the mouth

Also Published As

Publication number Publication date
RU2019103647A (ru) 2020-08-28
JP7047236B2 (ja) 2022-04-05
KR102484678B1 (ko) 2023-01-03
US20190167596A1 (en) 2019-06-06
MX391116B (es) 2025-03-21
EP3275433A1 (en) 2018-01-31
EP3490535A1 (en) 2019-06-05
KR20190034563A (ko) 2019-04-02
US11883538B2 (en) 2024-01-30
AU2017303333B2 (en) 2023-03-30
JP2019523305A (ja) 2019-08-22
RU2019103647A3 (enExample) 2020-10-12
US20240216282A1 (en) 2024-07-04
EP3490535B1 (en) 2021-07-14
MX2019001190A (es) 2019-09-06
AU2017303333A1 (en) 2019-03-14
PT3490535T (pt) 2021-09-30
CA3032211A1 (en) 2018-02-01
US12220487B2 (en) 2025-02-11
DK3490535T3 (da) 2021-10-04
WO2018019997A1 (en) 2018-02-01
BR112019001826A2 (pt) 2019-05-07
ES2891355T3 (es) 2022-01-27
RU2750670C2 (ru) 2021-06-30

Similar Documents

Publication Publication Date Title
JP5653218B2 (ja) アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
EA003663B1 (ru) Быстро дезинтегрирующие таблетки на основе метилцеллюлозы
MX2008014554A (es) Forma nueva de administracion de racecadotril.
US20170095507A1 (en) Dispersion preparation containing colloidal bismuth pectin and preparing method therefor
MXPA03002769A (es) Formulacion farmaceutica de liberacion sostenida e independiente de la densidad ionica.
JP2011503010A (ja) 水分封鎖剤を使用する湿式顆粒化
Rahamathulla et al. 23 factorial design and optimization of effervescent floating matrix tablet of neratinib
US12220487B2 (en) Sustained release compositions comprising micronized tolcapone
EP0869783B1 (en) Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof
JP2008534621A (ja) リオチロニンからなる放出制御型医薬組成物、並びにその製造方法及び使用方法
KR20250036933A (ko) 타파미디스 약학 조성물
CN105106963B (zh) 马来酸曲美布汀缓释制剂及其制备方法
TWI651085B (zh) Ｎ－［５－［２－（３，５－二甲氧基苯基）乙基］－２ｈ－吡唑－３－基］－４－［（３ｒ，５ｓ）－３，５－二甲基哌－１－基］苯甲醯胺之醫藥調配物
EP3349733A1 (de) Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung
Rambabu et al. The study of Guar gum and starch on disintegration time and drug release of fast dissolving tablet in rabbit using single dose randomized parallel design method
CN103860497A (zh) 一种美洛昔康分散片及其制备方法
CA3032211C (en) Sustained release composition comprising micronized tolcapone
CN112137971A (zh) 一种甘磷酸胆碱的口腔崩解片及其制备方法
CN103877041B (zh) 一种吡罗昔康分散片及其制备方法
Nagaraja et al. Formulation Development and Optimization of Tramadol Hydrochloride Fast Dissolving Tablets with Natural Superdisintegrant
EP2732812A1 (de) Pramipexol-Retardtablettenformulierung
Chaturvedi et al. Impact of superdisintegrants on the release of oro-dispersible tablets of losartan potassium: A comparative analysis
CN106074421A (zh) 一种提高稳定性的药物组合物
JP2006257068A (ja) 高含量塩酸テルビナフィン錠剤およびその製造方法
TW202510865A (zh) 藥物組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008562

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190521

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40008562

Country of ref document: HK